TIMI Study Group, Boston, MA   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Boston MA United States (1984)

Organization Overview

First Clinical Trial
2004
NCT00099788
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

TIMI | TIMI Study Group | TIMI Study Group, Boston, MA, USA | TIMI Study Group, MA, USA

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Death (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Dyslipidemias (Phase 2)

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Infarction (Phase 3)

Ischemia (Phase 3)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

ST Elevation Myocardial Infarction (Phase 2)

Stroke (Phase 3)

Syndrome (Phase 3)

Thromboembolism (Phase 4)

Thrombosis (Phase 4)

Venous Thromboembolism (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 13